Commentary
Volume 07:05, 2024

Journal of Clinical Neurology and Neurosurgery

ISSN: 2684-6012 Open Access

Glioblastoma Management with the Ketogenic Diet in Cancer Neuroscience

Tomassini Fitoz*

Department of Biology, Palmetto General Hospital, Hialeah, FL 33313, USA

Introduction

Glioblastoma (GBM) is one of the most aggressive and difficult-to-treat brain cancers, often leading to poor prognosis despite the best conventional treatments. It is characterized by its rapid growth, highly invasive nature and resistance to treatment. While surgery, radiation therapy and chemotherapy remain the cornerstone of GBM treatment, there is an increasing interest in exploring adjunctive therapies that could enhance the efficacy of these conventional methods. One such approach that has gained attention in recent years is the Ketogenic Diet (KD), a high-fat, low-carbohydrate diet that has shown potential in managing several forms of cancer, including glioblastoma. In cancer neuroscience, the study of how the ketogenic diet can impact glioblastoma is a developing area of research, with promising results suggesting that the KD may offer a novel therapeutic strategy for this challenging condition [1].

Description

The ketogenic diet works by shifting the body's metabolism from glucose to ketones, which are produced by the liver from fats in the absence of sufficient carbohydrates. Normally, cancer cells, including those of glioblastoma, rely heavily on glucose as their primary energy source through a phenomenon known as the Warburg effect. This metabolic shift makes tumor cells highly dependent on glucose for survival and growth. However, by restricting carbohydrate intake and inducing a state of ketosis, the ketogenic diet deprives the tumor cells of glucose while providing an alternative energy source in the form of ketones. This metabolic stress can potentially slow the growth of glioblastoma cells and render them more susceptible to the effects of conventional treatments like radiation and chemotherapy.

In addition to altering the energy metabolism of tumor cells, the ketogenic diet has been shown to exert a number of other beneficial effects that could contribute to the management of glioblastoma. One of the most important aspects is its impact on the tumor microenvironment. Glioblastomas are known to create a unique environment that supports their growth and invasiveness, including factors such as hypoxia (low oxygen levels), acidosis and inflammation. The ketogenic diet may help modulate these factors, particularly by reducing inflammation. Inflammatory signaling pathways are often upregulated in GBM, contributing to tumor progression and resistance to treatment. By lowering systemic inflammation, the ketogenic diet may help reduce the growth and spread of glioblastoma cells. Moreover, the ketogenic diet's ability to improve mitochondrial function is another aspect that has attracted attention in cancer neuroscience. Mitochondria play a crucial role in cellular energy production and apoptosis (programmed cell death). Cancer cells often have dysfunctional mitochondria, which helps them evade apoptosis and survive in the hostile environment of a tumor [2,3].

Recent research has also focused on the potential synergistic effects of combining the ketogenic diet with traditional glioblastoma treatments. Preclinical studies have demonstrated that a ketogenic diet, when used alongside radiation therapy, can improve the efficacy of the treatment. One study in animal models showed that combining the ketogenic diet with radiation resulted in a reduction in tumor growth compared to radiation alone. Similarly, the ketogenic diet has been investigated for its potential to enhance the effectiveness of chemotherapy agents, such as temozolomide, which is commonly used in glioblastoma treatment. By reducing the glucose availability to tumor cells, the ketogenic diet may make them more sensitive to the cytotoxic effects of chemotherapy drugs.

In clinical settings, the use of the ketogenic diet in glioblastoma management is still being investigated, with mixed results. Early clinical trials have shown that some patients with GBM may experience improvements in their quality of life, including reduced fatigue and improved cognitive function, when following a ketogenic diet. These improvements are thought to be due to the neuroprotective effects of ketones, which provide an efficient energy source for the brain and may help support brain function during cancer treatment. Additionally, some patients have experienced tumor stabilization or a slower rate of progression when the ketogenic diet is used as an adjunctive treatment. However, it is important to note that the clinical evidence is still limited and more rigorous, large-scale studies are needed to fully understand the effectiveness and safety of the ketogenic diet in GBM management [4,5].

Conclusion

Despite the challenges, the potential benefits of the ketogenic diet in managing glioblastoma are undeniable. Research into its effects on brain tumors has provided promising insights into how altering cellular metabolism can influence cancer progression. The ketogenic diet may not only improve the effectiveness of conventional therapies but also provide a targeted approach to slowing the growth of glioblastoma cells. With further research, including well-designed clinical trials, we may gain a deeper understanding of how to best integrate the ketogenic diet into glioblastoma treatment protocols. The ketogenic diet offers a novel and potentially valuable approach to managing glioblastoma, an aggressive and treatment-resistant brain cancer. By shifting the metabolic state of tumor cells and the surrounding environment, the ketogenic diet may slow the progression of glioblastoma and enhance the effectiveness of conventional treatments such as radiation and chemotherapy. Although research is still in its early stages, the potential for improving patient outcomes, both in terms of tumor control and quality of life, is significant. With continued investigation, the ketogenic diet could become a critical component of a comprehensive, multi-modal approach to glioblastoma management, offering hope for patients who face one of the most difficult challenges in modern oncology.

Acknowledgement

None.

***Address for Correspondence:** Tomassini Fitoz, Department of Biology, Palmetto General Hospital, Hialeah, FL 33313, USA, E-mail: tomassinnif@tz.edu*

Received: 01 October, 2024, Manuscript No. jcnn-24-154599; **Editor Assigned:** 03 October, 2024, Pre QC No. P-154599; **Reviewed:** 17 October, 2024, QC No. Q-154599; **Revised:** 22 October, 2024, Manuscript No. R-154599; **Published:** 29 October, 2024, DOI: 10.37421/2684-6012.2024.7.251

Conflict of Interest

None.

References

1. Sievert, Angela J. and Michael J. Fisher. "Pediatric low-grade gliomas." *J Child Neurol* 24 (2009): 1397-1408.
2. Sargaço, Beatriz, Patrícia Almeida Oliveira, Maria Luz Antunes and Ana Catarina Moreira. "Effects of the ketogenic diet in the treatment of gliomas: A systematic review." *Nutrients* 14 (2022): 1007.
3. Tagliabue, A., M. Armeno, K. A. Berk and M. Guglielmetti, et al. "Ketogenic diet for epilepsy and obesity: Is it the same?." *Nutr Metab Cardiovasc Dis* 34 (2024): 581-589.
4. Winter, Sebastian F., Franziska Loebel and Jorg Dietrich. "Role of ketogenic metabolic therapy in malignant glioma: A systematic review." *Crit Rev Oncol Hematol* 112 (2017): 41-58.
5. Boveri, Theodor. "Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris." *J Cell Sci* 121(2008): 1-84.

How to cite this article: Fitoz, Tomassini. “Glioblastoma Management with the Ketogenic Diet in Cancer Neuroscience.” *J Clin Neurol Neurosurg* 7 (2024): 251.